Clinuvel Pharmaceuticals Limited Share Price Deutsche Boerse AG
Stocks
UR9
AU000000CUV3
Pharmaceuticals
OTC Markets Traded|
Real-time Estimate
Tradegate
11:40:47 24/09/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 5.008 EUR | +2.20% |
|
0.00% | -30.00% |
| Market Cap | 42Cr 29Cr 26Cr 24Cr 22Cr 41Cr 2.8TCr 290.69Cr 112.65Cr 1.43TCr 109.69Cr 107.31Cr 4.64TCr | P/E 2027 * |
11.6x | P/E 2028 * | 11x |
|---|---|---|---|---|---|
| Enterprise Value | 13Cr 9.3Cr 8.18Cr 7.71Cr 7.04Cr 13Cr 892.98Cr 93Cr 36Cr 454.48Cr 35Cr 34Cr 1.48TCr | EV / Sales 2027 * |
1.4x | EV / Sales 2028 * | 0.96x |
| Free-Float |
83.79% | Yield 2027 * |
0.66% | Yield 2028 * | 0.79% |
| Markets | Quality | ||
|---|---|---|---|
Australian S.E.
| CUV | Delayed | |
Tradegate
| UR9 | Real-time | |
|
Boerse Muenchen
| UR9 | Real-time | |
|
OTC Markets
| CLVLF | Delayed | |
|
Berne S.E.
| UR9 | End-of-day quote | |
|
Deutsche Boerse AG
| UR9 | Delayed | |
|
Börse Stuttgart
| UR9 | Delayed |
Last Transcript: Clinuvel Pharmaceuticals Limited
| 1 day | +2.20% | ||
| Current month | -2.97% | ||
| 1 month | -22.30% | ||
| 3 months | -14.04% | ||
| 6 months | -16.38% | ||
| Current year | -30.00% |
| 1 week | 4.9 |  | 4.9 |
| 1 month | 4.9 | | 6.7 |
| Current year | 4.9 | | 7.39 |
| 1 year | 4.9 | | 7.45 |
| 3 years | 4.8 | | 10.94 |
| 5 years | 4.8 | | 26.7 |
| 10 years | 4 | | 27 |
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 63 | 01/11/2005 |
Peter Vaughan
DFI | Director of Finance/CFO | 42 | 30/06/2024 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Karen Agersborg
BRD | Director/Board Member | - | 29/01/2018 |
Susan Smith
BRD | Director/Board Member | - | 23/09/2019 |
| Chairman | - | 01/01/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.20% | 0.00% | - | - | 29Cr | |
| -0.54% | +0.99% | +38.18% | -4.48% | 8.01TCr | |
| +4.69% | +19.47% | +629.68% | +92.36% | 7.27TCr | |
| -0.07% | +2.70% | -10.41% | -28.96% | 6.05TCr | |
| -1.80% | -3.05% | -14.24% | +26.38% | 4.62TCr | |
| +0.14% | +1.58% | +3.62% | +165.87% | 4.6TCr | |
| +0.16% | +3.81% | +65.18% | -10.83% | 3.36TCr | |
| -0.09% | -2.52% | +47.83% | +111.76% | 2.53TCr | |
| -3.48% | +6.06% | +6.80% | +166.49% | 2.3TCr | |
| -0.82% | -2.20% | +57.40% | +97.29% | 1.54TCr | |
| Average | +0.04% | +5.23% | +91.56% | +68.43% | 4.47TCr | |
| Weighted average by Cap. | +0.33% | +6.70% | +129.52% | +52.72% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 9.49Cr 6.65Cr 5.85Cr 5.52Cr 5.03Cr 9.41Cr 638.68Cr 66Cr 26Cr 325.05Cr 25Cr 24Cr 1.06TCr | 10Cr 7.23Cr 6.36Cr 5.99Cr 5.47Cr 10Cr 693.63Cr 72Cr 28Cr 353.02Cr 27Cr 27Cr 1.15TCr |
| Net income | 3.6Cr 2.53Cr 2.22Cr 2.09Cr 1.91Cr 3.57Cr 242.48Cr 25Cr 9.74Cr 123.41Cr 9.48Cr 9.28Cr 401.59Cr | 3.81Cr 2.67Cr 2.35Cr 2.22Cr 2.02Cr 3.78Cr 256.51Cr 27Cr 10Cr 130.55Cr 10Cr 9.82Cr 424.82Cr |
| Net Debt | -28Cr -20Cr -18Cr -17Cr -15Cr -28Cr -1.91TCr -198.13Cr -77Cr -972.77Cr -75Cr -73Cr -3.17TCr | -32Cr -22Cr -20Cr -18Cr -17Cr -31Cr -2.14TCr -221.44Cr -86Cr -1.09TCr -84Cr -82Cr -3.54TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/26/24 | €4.900 | 0.00% | 0 |
| 23/26/23 | €4.900 | 0.00% | 0 |
| 22/26/22 | €4.900 | 0.00% | 0 |
| 21/26/21 | €4.900 | 0.00% | 0 |
| 18/26/18 | €4.900 | 0.00% | 0 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CUV Stock
- UR9 Stock
Select your edition
All financial news and data tailored to specific country editions
